Hiltonol® plus Dendritic Cell Vaccine for Recurrent Glioblastoma

Date: Apr 30, 2007
Source: ( click here to go to the source)

Featured firm in this article: Oncovir Inc of Washington, DC

Oncovir is pleased to announce the opening of a new clinical trial of Hiltonol® plus a dendritic cell vaccine targeting specific brain tumor antigens in patients with recurrent glioblastoma. The study is being conducted by Dr. Hideho Okada at the University of Pittsburgh Medical Center.

Recent News

11132023	Selecta Biosciences Announces Merger with Cartesian Therapeutics Cartesian Therapeutics Inc (3 awards)
09252023	AcuraStem Enters into a License Agreement with Takeda to Advance PIKFYVE Therapeutics AcuraStem Inc (5 awards)
08222023	Grander Closes Acquisition of PolarityTE, Inc. Assets PolarityTE Inc (1 awards)
08082023	Alchemist Completes Acquisition of Aqueous Resources LLC, a Leader in Industrial Brine Pre-Treatment Solutions and Direct Lithium Extraction Aqueous Resources LLC (1 awards)
08082023	Arcfield Acquires Strategic Technology Consulting Strategic Technology Consulting LLC (1 awards)
08072023	Xenesis to send optical terminal to ISS platform Xenesis Inc (2 awards)
07202023	Advanced Sustainable Aviation Fuels Gain Momentum as AIR COMPANY Announces Collaboration with Air Canada Air Company Holdings Inc (2 awards)
07182023	Durham-based Novan Inc. sells all assets, files for bankruptcy Novan Inc (8 awards)
07172023	Novartis Acquires DTx Pharma in Potential $1B Deal DTx Pharma LLC (5 awards)
05312023	Adaract Awarded $400,000 from AngelNV and State Small Business Initiative (SSBCI) ADARACT (1 awards)

New To Inknowvation.com?

News Article

Recent News